Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyNeuro-OncologyThoracic TumorsTumor, regardless of entityDiseaseBreast CancerLung Carcinoma, Non-Small CellLung Carcinoma, Small CellMalignant MeningitisTumor, Various OrgansSubgroupER+ESR1-MutationgBRCA mutationHER2+HER2-lowHR+HR+ postmenopausalHR+ premenopausalPD-L1+PIK3CA mutationpostmenopausaltripel negativeunfitICD10C34.-C50.-C79.3MeSHBreast NeoplasmsCarcinoma, Non-Small-Cell LungMeningeal CarcinomatosisSmall Cell Lung CarcinomaTriple Negative Breast NeoplasmsSequenceAC (DOXO60/CYCL600) dose-dense x 4 followed by PACL175 x 4, Breast Ca, adj., A (PID402) -|- AC (DOXO60/CYCL600) dose-dense x 4 followed by PACL175 x 4, Breast Ca, adj., B (PID403)AC (DOXO60/CYCL600) x 4 followed by DOCE100 x 4, Breast Ca, adj., A (PID599) -|- AC (DOXO60/CYCL600) x 4 followed by DOCE100 x 4, Breast Ca, adj., B (PID395)AC (DOXO60/CYCL600) x 4 followed by PACL, Breast Ca, adj., A (PID394) -|- AC (DOXO60/CYCL600) x 4 followed by PACL80 x 12, Breast Ca, adj., B (PID397)AC (DOXO60/CYCL600) x 4 followed by PACL, Breast Ca, adj., A (PID394) -|- AC (DOXO60/CYCL600) x 4 followed by PACL175 x 4, Breast Ca, adj., B (PID396)AC (DOXO60/CYCL600) x 4 followed by PACL, Breast Ca, adj., A (PID394) -|- B C1 (PID491) -|- B C2+ (PID492) -|- TRAS6 (PID1474)ALTERNATIVE: TRAS8/LAPA1000/LETC2.5, Breast Ca, C1 (PID1768) -|- TRAS6/LAPA1000/LETC2.5, Breast Ca, C2+ (PID1769)APHINITY: PERT840/TRAS8/DOCE75, Breast Ca adj., C1 (PID1165) -|- C2-4 (PID1166) -|- C5-18 (PID680)APHINITY: PERT840/TRAS8/PACL80, Breast Ca, adj., C1 (PID1167) -|- C2-4 (PID1168) -|- C5-18 (PID680)Atezolizumab 840 / Nab-Paclitaxel 125, Breast Cancer, neoadjuvant, C1-3 (PID2423) -|- Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamide 600, C4-5 (PID2424) -|- ATEC1200, adj. (PID2425)CALGB 40302: LAPA1500/FLVS(500/250), Breast Ca, C1 (PID1770) -|- LAPA1500/FLVS250, Breast Ca, C2+ (PID1771)CAPE1000/DOCE75, Breast Ca, adj., A (PID1643) -|- CAPE1000/EPIR75/CYCL500, B (PID1644)CLEOPATRA: PERT840/TRAS8/DOCE75, Breast Ca, C1 (PID361) -|- PERT420/TRAS6/DOCE75, Breast Ca, C2+ (PID364)DOXO60 x 4 / PACL175 x 4 / CYCL600 x 4, Breast Ca, adj., A (PID1141) -|- B (PID1142) -|- C (PID1143)EC (EPIR90/CYCL600), Breast Ca, adj. (PID579) -|- PACL80, Breast Ca, adj. (PID581)EC (EPIR90/CYCL600) x 4 followed by DOCE100, Breast Ca, neoadj., A (PID404) -|- EC (EPIR90/CYCL600) x 4 followed by DOCE100, Breast Ca, neoadj., B (PID405)eLEcTRA: TRAS8/LETR2.5, Breast Ca, C1 (PID764) -|- TRAS6/LETR2.5, Breast Ca, C2+ (PID765)EPIR90 x 4 / PACL175 x 4 / CYCL600 x 4, dose-dense, Breast Ca, adj., A (PID86) -|- B (PID87) -|- C (PID88)EPIR150 x 3 / PACL225 x 3 / CYCL2500 x 3, dose-dense, Breast Ca, adj., A (PID399) -|- B (PID400) -|- C (PID401)EVER10/FLVS500, Breast Ca, C1 (PID1875) -|- C2+ (PID1876)FEC (FU500/EPIR100/CYCL500) x 3 followed by DOCE100 x 3, Breast Ca, adj., A (PID388) -|- FEC (FU500/EPIR100/CYCL500) x 3 followed by DOCE100 x 3, Breast Ca, adj., B (PID389)FeDeriCa: AC (DOXO60/CYCL600) dose-dense x 4 followed by PACL175 x 4, Breast Ca, adj., A (PID402) -|- B C1 (PID1753) -|- AB C2-4 (PID1754) -|- C5-18 (PID1755)FeDeriCa: AC (DOXO60/CYCL600) x 4 followed by DOCE100 x 4, Breast Ca, adj., A (PID599) -|-B C1 (PID1751) -|- B C2-4 (PID1752) -|- C5-18 (PID1755)GBG 69-GeparSepto: PERT840/TRAS8/NPAC125, Breast Ca, neoadj., C1 (PID1355) -|- C2-4 (PID1356) -|- PERT420/TRAS6, adj. (PID1350).GEMC1000/CRBP4/TRAS8, Breast Ca, C1 (PID413) -|- GEMC1000/CRBP4/TRAS6, Breast Ca, C2+ (PID414)HER2CLIMB: TUCA300/CAPE1000/TRAS8, Breast Ca, C1 (PID1761) -|- TUCA300/CAPE1000/TRAS6, C2+ (PID1762)HERNATA: TRAS8/DOCE100, Breast Ca, C1 (PID416) -|- TRAS6/DOCE100, Breast Ca, C2+ (PID417)HERNATA: TRAS8/VINO30, Breast Ca, C1 (PID418) -|- TRAS6/VINO30, Breast Ca, C2+ (PID419)KEYNOTE-355: PEMB200/CRBP2/GEMC1000, Breast Ca (PID1933) -|- PEMB200, maint. (PID1931)KEYNOTE-355: PEMB200/NPAC100, Breast Ca (PID1930) -|- PEMB200, Maint. (PID1931)KEYNOTE-355: PEMB200/PACL90, Breast Ca (PID1932) -|- PEMB200, maint. (PID1931)KEYNOTE-522: PEMB200/PACL80/CRBP5, Breast Ca, neoadj., C1-4 (PID1464) -|- C5-8 (PID1465) or C5-8 (PID1466) -|- C9-17 (PID1868)MONARCH 2: ABEM150/FLVS500, Breast Ca, C1 (PID1408) -|- ABEM150/FLVS500, Breast Ca, C2+ (PID1409)monarcHER: TRAS8/ABEM150/FLVS500, Breast Ca, C1 (PID1601) -|- TRAS6/ABEM150/FLVS500, C2+ (PID1602)Neoadjuvant WSG-TP-II (Letrozole)Neoadjuvant WSG-TP-II (Paclitaxel)Neoadjuvant WSG-TP-II (Tamoxifen) -|- PERT840/TRAS8/TMXF20, Breast Ca, adj., C1 (PID2450)NeoSphere Arm B: PERT840/TRAS8/DOCE75, Breast Ca, neoadj., C1 (PID589) -|- C2-4 (PID750) -|- FEC adj. (PID759) -|- TRAS6 adj. (PID1474)NPAC100/CYCL600/TRAS8, Breast Ca, adj. C1 (PID409) -|- NPAC100/CYCL600/TRAS6, Breast Ca, adj. C2+ (PID410)NPAC125/TRAS(4/2), Breast Ca C1 (PID427) -|- NPAC125/TRAS2, Breast Ca C2+ (PID428)PACL80/TRAS4, Breast Ca, adj., C1 (PID932) -|- PACL80/TRAS2, Breast Ca, adj., C2-12 (PID933)PALOMA3: PALB125/FLVS500, Breast Ca, C1 (PID607) -|- PALB125/FLVS500, Breast Ca, C2+ (PID822)PERTAIN: PERT840/TRAS8/ANAS1, Breast Ca, C1 (PID1498) -|- PERT420/TRAS6/ANAS1, Breast Ca, C2+ (PID1500)PERTAIN: PERT840/TRAS8/LETR2.5, Breast Ca, C1 (PID1496) -|- PERT420/TRAS6/LETR2.5, Breast Ca, C2+ (PID1497)SAPPHIRE: PERT1200/TRAS600/NPAC125, Breast Ca, C1 (PID1756) -|- C2+ (PID1757) -|- maint. (PID1760)SAPPHIRE: PERT1200/TRAS600/PACL80, Breast Ca, C1 (PID1758) -|- C2+ (PID1759) -|- maint. (PID1760)SOLAR-1: ALPE300/FLVS500, Breast Ca, C1 (PID1620) -|- ALPE300/FLVS500, Breast Ca, C2+ (PID1621)TAnDEM: TRAS(4/2)/ANAS1, Breast Ca, C1 (PID755) -|- TRAS2/ANAS1, Breast Ca, C2+ (PID756)TCH (DOCE75/CRBP6/TRAS(4/2)), Breast Ca, adj., C1 (PID411) -|- C2+ (PID412) -|- TRAS6 adj. (PID1474)TCH (DOCE75/CRBP6/TRAS8), Breast Ca, neoadj., C1 (PID655) -|- C2+ (PID654) -|- TRAS8, adj., C1 (PID1687) -|- C2+ (PID1474)TRAIN-2: PERT840/TRAS8/PACL80/CRPB6, Breast Ca, neoadj., C1 (PID2121) -|- PERT420/TRAS6/PACL80/CRPB6, C2-9 (PID2122)TRAS8, Breast Ca, adj., C1 (PID1687) -|- TRAS6, Breast Ca, adj., C2+ (PID1688)TRAS8, Breast Ca, C1 (PID384) -|- TRAS6, Breast Ca, C2+ (PID385)TRAS8, met. Breast Ca, C1 (PID761) -|- TRAS6, met. Breast Ca, C2+ (PID760)TRAS80, Malignant Meningitis, C1 (PID2526) -|- C2 (PID2527) -|- C3+ (PID2542)TRYPHAENA Arm A: FEC (FU500/EPIR90/CYCL600)/TRAS8/PERT840, Breast Ca, neoadj., C1 (PID1467) -|- C2-3 (PID1468) -|- PERT420/TRAS6/DOCE75, C4-6 (PID750) -|- TRAS6, adj. (PID1474)TRYPHAENA Arm B: FEC (FU500/EPIR90/CYCL600), Breast Ca, neoadj., C1-3 (PID1357) -|- PERT840/TRAS8/DOCE75, C4 (PID589) -|- C5-6 (PID750) -|- TRAS6, adj. (PID1474)TRYPHAENA Arm C: PERT840/TRAS8/DOCE75/CRBP6, Breast Ca, neoadj., C1 (PID1469) -|- C2-6 (PID1470) -|- TRAS6, adj. (PID1474)VINO25/CAPE1000, Breast Ca (PID1692) -|- VINO25/CAPE1000 - CAPE1000 maint., Breast Ca (PID1693)VINO60/CAPE1000, Breast Ca, C1 (PID942) -|- VINO80/CAPE1000, C2+ (PID943)ChemotherapyChemo-substanceAbemaciclibAlpelisibAnastrozoleAtezolizumabAvelumabBevacizumabCapecitabineCarboplatinCisplatinCyclophosphamideDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalElacestrantEpirubicinEribulinEverolimusExemestaneFluorouracilFulvestrantGemcitabineGoserelinHydrocortisoneLapatinibLetrozoleLeuprorelinMargetuximabMethotrexateMitoxantroneNab-paclitaxelNeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTrofosfamideTucatinibVinorelbineChemo-substanceAbemaciclibAlpelisibAnastrozoleAtezolizumabAvelumabBevacizumabCapecitabineCarboplatinCisplatinCyclophosphamideDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalElacestrantEpirubicinEribulinEverolimusExemestaneFluorouracilFulvestrantGemcitabineGoserelinHydrocortisoneLapatinibLetrozoleLeuprorelinMargetuximabMethotrexateMitoxantroneNab-paclitaxelNeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTrofosfamideTucatinibVinorelbineChemo-substanceAbemaciclibAlpelisibAnastrozoleAtezolizumabAvelumabBevacizumabCapecitabineCarboplatinCisplatinCyclophosphamideDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalElacestrantEpirubicinEribulinEverolimusExemestaneFluorouracilFulvestrantGemcitabineGoserelinHydrocortisoneLapatinibLetrozoleLeuprorelinMargetuximabMethotrexateMitoxantroneNab-paclitaxelNeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTrofosfamideTucatinibVinorelbineChemo-substanceAbemaciclibAlpelisibAnastrozoleAtezolizumabAvelumabBevacizumabCapecitabineCarboplatinCisplatinCyclophosphamideDocetaxelDoxorubicinDoxorubicin liposomalDoxorubicin pegylated liposomalElacestrantEpirubicinEribulinEverolimusExemestaneFluorouracilFulvestrantGemcitabineGoserelinHydrocortisoneLapatinibLetrozoleLeuprorelinMargetuximabMethotrexateMitoxantroneNab-paclitaxelNeratinibOlaparibPaclitaxelPalbociclibPembrolizumabPertuzumabRibociclibTalazoparibTamoxifenThiotepaTopotecanTrastuzumabTrastuzumab DeruxtecanTrastuzumab emtansineTrofosfamideTucatinibVinorelbineNo. Substances12345 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineClodronic acidDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronLoperamideMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineZoledronic AcidSupportive substanceBalanced Crystalloid SolutionCimetidineClodronic acidDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronLoperamideMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineZoledronic AcidSupportive substanceBalanced Crystalloid SolutionCimetidineClodronic acidDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronLoperamideMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineZoledronic AcidSupportive substanceBalanced Crystalloid SolutionCimetidineClodronic acidDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronLoperamideMagnesiumMagnesium sulfateMesnaParacetamolPegfilgrastimPotassium chloridePrednisolonePyridoxineZoledronic AcidNo. Substances1234567Protocol classificationTherapy classificationalternativecurrent standardstudy analogStudy protocol, currentIntensityDose denseDose intensifiedLow doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseInductionMaintenanceneoadjuvantneoadjuvant / adjuvantpost-neoadjuvantseveral possibleTherapy intentioncurativedisease controlpalliativesupportiveRisksAbdominal PainAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArachnoiditisArthalgiaAstheniaBone PainCardiotoxicityColitisConjunctivitisConstipationDepressionDiarrheaDrowsinessDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueFebrile NeutropeniaFlu-like SymptomsGastrointestinal ToxicityHand-Foot SyndromeHeadacheHeart FailureHematuriaHemorrhageHepatotoxicityHyperbilirubinemiaHyperglycemiaHypertensionHyperthyroidismHypertriglyceridemiaHypocalcemiaHypokalemiaHyponatremiaHypophosphatemiaHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMyalgiasNail ChangesNauseaNeuropathyNeurotoxicityNeutropeniaOral MucositisOsteonecrosis of the JawOsteopeniaPainPneumoniaPneumonitisPruritusPyrexiaRashSeizuresTachycardiaTear DropThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVisual DisturbancesVomiting only studiesPublicationAuthorAdams SAddeo RAl-Batran SAlbain KSAndersson MAndre FBaselga JBastholt LBatist GBayraktar SBidard FCBudd GTBurstein HJChan AChan SCinieri SCitron MLColeman RColleoni MCoombes RCCortes JDecker TDenise YardleyDiel IDi Leo ADirix LEarly Breast Cancer Trialists Collaborative Group (EBCTCG)Finn RGasparini G Geyer CEGianni LGianni L / Schneeweiss AGluz OGnant MGoetz MGradishar WJGroves MHamilton EHarbeck NHarvey VHeidemann EHochster HHortobagyi GHuober JHu XCIm SAJackisch CJ CarmichaelJohnston SRDJones EKaufman BKorblum NKotake MKrop IEKumthekar PLang ILangley RELi JLitton JLiu YLoesch DLück HJMaisch BMalinovszky K Martin MMartinoni A Masuda NMehta RSMinckwitz GMirtsching BMittendorf EModi SMoebus VMontagna EMross KMurthy RKMuss HBNabholtz JMO'Shaughnessy JOberkampf FPark YHPerez EA Perrone FPiccart MRimawi MRivera ERobson MRoché HRomond EHRugo HSSaura CSawaki MSchmid PSchneeweiss ASeidman ADSenkus ESharma PSikov WMSlamon DSledge GWSmith ISparano JAStemmer HJStockler MRTan ARThe Netherlands Cancer InstituteTolaney STolaney SMTurner NCTutt ATutt ANJUntch Mvan Ramshorst MSVerma Svon Minckwitz GWang JWoodward NYardley DYardley DADiseasefortgeschrittenes Mamma-Ca, Erstliniefortgeschrittenes Mamma-Ca, HR+, HER-2-, ECOG 0-1fortgeschrittenes Mamma-Ca, ungeeignet für intensivere Chemotherapiefortgeschrittenes Mamma-Ca, Zweitlinie, ECOG 0-2fortgeschrittenes Mammakarzinom, HR+, HER2-, Erstlinie, ECOG 0-1fortgeschrittenes metastasiertes MammakarzinomFortgeschrittenes oder metastasiertes Mammakarzinom, HR+, Her2-, nach endokriner Vortherapie, ECOG 0-1fortgeschrittenes oder rezidiviertes Mammakarzinom, HR+, Her2neu+, ECOG 0-1, mind. 2 anti-Her2-Vortherapien im palliativen SettingHER2+ Brustkrebs, adjuvant oder neoadjuvant, ECOG 0-2HER2+ Brustkrebs, neoadjuvant, ECOG 0-2HER2+ Mamma-Ca, adjuvante Erhaltung nach neoadjuvanter ChemotherapieHER2+ Mamma-Ca, adjuvante Therapie, 70-80 J.HER2+ Mamma-Ca, ErhaltungHER2+ und Hormonrezeptor +, metastasiertes Mamma-Ca, postmenopausalm, ECOG 0-1HER2+ und HR+, lokal fortgeschrittenes oder metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1HER2+ und HR+, lokal fortgeschrittenes oder metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1HER2+ und HR+, metastasiertes Mamma-Ca, postmenopausal, ECOG 0-1Hormon Rezeptor +, HER2 -, fortgeschrittenes oder wiederkerhrendes Mammakarzinom während vorangegangengener endokriner Therapie, ECOG 0-1Hormon Rezeptor +, HER2 -, fortgeschrittenes oder wiederkerhrendes Mammakarzinom während vorangegangengener endokriner Therapie.Hormon Rezeptor +, HER2 -, lokal fortgeschrittenes Mammakarzinom, Erstlinie, ECOG 0-2Leptomeningeale Metastasen beim Mamma-Ca, HER2+, ECOG 0-3Leptomeningeale Metastasen beim Mamma-Ca, HER2+, Karnofsky >50lokal fortgeschrittenes, nicht resezierbares oder metastasierendes Mamma-Ca, triple neg., Erstlinie, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Mamma-Ca, Her2+, mindestens 2 gegen HER2 gerichtete Behandlungsschemata, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Mamma-Ca, Zweitlinie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Mammakarzinom, BRCA-Mutation, Her2-, ECOG 0-2, bis 3 vorausgegangene ChemotherapielinienLokal fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, HER2+, nach vorangegangener endokriner Therapie.Lokal fortgeschrittenes oder metastasiertes Mammakarzinom, HR+, HER2+, postmenopausal, ECOG 0-1Maligner Perikarderguss, hämodynamisch relevantMaligner Perikarderguss beim Mamma-Ca, hämodynamisch relevantMamma-Ca, adjuvantMamma-Ca, adjuvant, ECOG 0-1, Beginn innerhalb von 42 Tagen nach der OPMamma-Ca, adjuvant, ECOG 0-1, Beginn innerhalb von 42 Tagen nach der OPMamma-Ca, HER2+, adjuvantMamma-Ca, HER2+, ECOG 0-2Mamma-Ca, HER2+, nach neoadjuvanter ChemotherapieMamma-Ca, high risk, Stadium I-III, adjuvantMamma-Ca, high risk, Stadium I-III oder 0-3 befallene Lymphknoten, adjuvantMamma-Ca, LK-positiv, adjuvantMamma-Ca, met. oder fortgeschr., ER+, postmenopausalMamma-Ca, metastasiert oder hohes Rezidivrisiko, 65-79 Jahre, adjuvant, ECOG 0-1Mamma-Ca, metastasiert oder rezidiviert, prämenopausal, HR+, HER2-, ECOG 0-2Mamma-Ca, nach neoadjuvanter Chemotherapie, HER2-negativ, ECOG 0-1Mamma-Ca, neoadjuvantMamma-Ca, operabel, Stadium II–IIIC, Her2+, ECOG 0-1Mamma-Ca, Stadium I-IV, adjuvantMamma-Ca, Stadium II oder III, HR+, HER2-, ECOG 0-1Mamma-Ca, tripel-negativ, ECOG 0-1Mamma-Ca, tripel-negativ, Stadium II/III, neoadjuvante TherapieMamma-Ca, tripel neg., operabel, Erstlinie, ECOG 0-1Mamma-Ca Stadium I und II, HR+, adjuvant, prämenopausalMammaCa, adjuvant, Paclitaxel wöchentlichMammakarzinom, adjuvant, 65 Jahre oder älter, ECOG 0-2Mammakarzinom, BRCA-Mutation, HER2-, ECOG 0-1Mammakarzinom, BRCA-Mutation, HER2-, nach neoadjuvanter oder adjuvanter taxan- und/oder anthrazyklinhaltiger Chemotherapie, ECOG 0-1Mammakarzinom, cT1c-T4a-c, cN0/N+, cM0, HER2+ (IHC/FISH), ECOG 0-1Mammakarzinom, Her2 negativ, metastasiert, nach mind. 2 Vortherapien, ECOG 0-1Mammakarzinom, Her2 pos., Drittlinie oder höher, ECOG 0-1Mammakarzinom, HER2+ und HR+, postmenopausal, ECOG 0-1Mammakarzinom, HR+, HER2-, Hochrisiko, adjuvantMammakarzinom, HR+, nodalpositiv (Stadium IIA-IIIC), ECOG 0-1Mammakarzinom, HR+, Stadium I-IIICMammakarzinom, lokal fortgeschritten oder metastasiert, ECOG 0-2Mammakarzinom, lokal fortgeschritten oder metastasiert, Her2+, nach vorheriger Therapie mit Trastuzumab Emtansin, ECOG 0-1Mammakarzinom, lokal fortgeschritten oder metastasiert, HR+, Her2-, PIK3CA mutiert, nach vorheriger endokriner TherapieMammakarzinom, lokal fortgeschritten oder metastasiert, mindestens 1 Vortherapie, inkl. adjuvante Behandlung, ECOG 0-2Mammakarzinom, metastasiert, Karnofsky-Score über 50, ZweitlinientherapieMammakarzinom, metastasiert, nach anthrazyklinhaltiger Chemotherapie, ECOG 0-1Mammakarzinom, postmenopausal, HR+ oder unbekannt, nach adjuvanter 2-3-jähriger Therapie mit TamoxifenMammakarzinom, Stadium I-III, HER2+, Trastuzumabtherapie bis zu 2 Jahren, ECOG 0-1Mammakarzinom, tripel-negativ, neoadjuvant, Erstlinie, ECOG 0-1Mammakarzinom, tripel negativ, ECOG 0-1Mammakarzinom, tripel negativ, Stadium I-IIIMammakarzinom, tripel negativ, ZweitlinieMammakarzinom, Östrogenrezeptor+, HER2-, ESR1-Mutation , Drittlinie nach CDK4/6-Inhibitor und Chemotherapie, ECOG 0-1Mammakarzinom adjuvant, HER2+, Tumor < 3 cmMammakarzinom Stadium IIA-IIIB, R0-Resektion, Karnofsky > 80met. Mamma-Ca, 2-5 Vortherapien (Taxan oder Anthracyclin enthaltend) oder 2 oder mehr Vortherapien bzgl. des met. Stadiums, ECOG 0-2met. Mamma-Ca, ECOG 0-2, Erstlinie im met. Stadium, im Falle anthrazyklinhaltiger Vortherapien (neo-/adj.) mehr 12 Monate Intervallmet. Mamma-Ca, Erst- bis Viertlinie im met. Stadium, kein Taxan in den pall. Vortherapienmet. Mamma-Ca, Erstlinie im met. Stadium nach vorangeg. neo-/adjuvanter anthrazyklinhaltiger Chemotherapiemet. Mamma-Ca , Erstlinie in met. Stadiummet. Mamma-Ca, Erstlinie in met. Stadiummet. Mamma-Ca, Erstlinie in met. Stadium, Patientinnen älter als 70 Jahremet. Mamma-Ca, Progress nach mehreren Therapienmet. Mamma-Ca, triple-negativ, Erstlinie im met. Stadium, ECOG 0-1met. Mamma-Ca HER2+, Drittlinie mit Trastuzumab, Lapatinib und Taxan in der Vortherapiemet. Mamma-Ca HER2+, Erstliniemet. Mamma-Ca HER2+, Progress nach Behandlung mit Regimen die Anthrazykline, Taxane und Trastuzumab beinhaltetenmet. Mamma-Ca HER2+, Zweitlinie nach Vorbehandlung mit Trastuzumab + Taxanmet. Mamma-Ca HER2negativ, ECOG 0-1, max. eine Vortherapie bzgl. der met. Erkrankungmet. Mamma-Ca HER2negativ, ECOG 0-2, Erstliniemet. Mamma-Ca HR+/HER2+, postmenopausal, Progress nach Behandlung mit endokriner Therapie oder Trastuzumab/Chemotherapie, ECOG 0-1metastasiertes, HER2+ Mamma-Ca, ECOG 0-2metastasiertes, tripel-negatives Mamma-Ca, PD-L1+, ECOG 0-1metastasiertes, triple-negatives Mamma-Ca, Erstlinie, ECOG 0-1metastasiertes Mamma-Ca, ECOG 0-1, vorbehandeltmetastasiertes Mamma-Ca, Erst- und Zweitlinientherapiemetastasiertes Mamma-Ca, Erstlinie, ECOG 0-2metastasiertes Mamma-Ca, Erstlinie, ohne anthrazyklinhaltige Vortherapie, ECOG 0-2metastasiertes Mamma-Ca, Erstlinie in metastasiertem Stadiummetastasiertes Mamma-Ca, Erstlinie in metastasiertem Stadium, ECOG 0-1metastasiertes Mamma-Ca, Erstlinientherapie, ECOG 0-3metastasiertes Mamma-Ca, HER2-, Erstlinie, Karnofsky > 70metastasiertes Mamma-Ca, HR+ postmenopausal, ECOG: 0-2metastasiertes Mamma-Ca, Progress nach mehreren Therapienmetastasiertes Mamma-Ca, tripel-negativ, Erstlinie, ECOG 0-1metastasiertes Mamma-Ca, triple-negativmetastasiertes Mamma-Ca, triple-negativ, ErstlinieMetastasiertes Mamma-Ca der Frau, ECOG 0-2, Erstlinientherapie, keine Herzinsuffizienz NYHA II-IV, kein Myokardinfarkt in den letzten 6 Mo.metastasiertes Mamma-Ca HER2 negativ, ECOG 0-2, ErstlinieMetastasiertes Mammakarzinom, ECOG 0-2Metastasiertes Mammakarzinom, ECOG 0-2, bis zu 2 VortherapienMetastasiertes Mammakarzinom, Karnofsky-Index über 60%, Drittlinie oder höhermetastasiertes Mammkarzinom, Rezidivtherapie, Karnofsky Status > 70%Metastasiertes oder lokal fortgeschrittenes Mamma-Ca, ERBB2-pos., mind. 2 VortherapienMetastasiertes oder lokal fortgeschrittenes Mamma-Ca, Her2-pos., mind. 2 Vortherapienoperables, lokal fortgeschrittenes Mamma-Ca, Tumor > 2cm, HER2+, ECOG 0-1operables, lokal fortgeschrittenes oder entzündliches Mamma-Ca, HER-2+, Erstlinie, ECOG 0-1Paclitaxel wöchentlich, Mamma-Ca, adjuvantPaclitaxel wöchentlich, MammaCa, adjuvantPaclitaxel wöchentlich, Mammakarzinom, adjuvantpostmenopausale Frauen, fortgeschr. Mamma-Ca, HR+, HER2-, Progress nach Anastrozol oder Letrozolprim. Brustkrebs, 18-65 Jahre, R0-Resektion, HER2+, Karnofsky Status > 80%prim. Brustkrebs, 18-65 Jahre, R0-Resektion, Karnofsky Status > 80%primäres Mamma-Caprimäres Mamma-Ca, adjuvant, HER2+primäres Mamma-Ca, HR+, HER2+, Karnofsky > 80Refraktäre Meningeosis neoplastica, Erstlinie für Meningeosis neoplastica, Karnofsky > 60residuelles invasives, nicht met. Mamma-Ca HER2+, nach neoadjuvanter Vorbehandlung mit Trastuzumab und Taxanrezidivierendes oder metastasiertes Mamma-Ca, postmenopausal, HR+, HER2-, Erstlinie, ECOG 0-1rezidivierendes oder metastasiertes Mamma-Ca, prä- und perimenopausal, HR+, HER2-, ECOG 0-1rezidiviertes oder metastasiertes Mammakarzinom, ECOG 0-2rezidiviertes oder metastasiertes Mammakarzinom, Zweitlinie, ECOG 0-2triple-negatives Mamma-Ca neoadjuvant, Erstlinie, Karnofsky Status > 80OriginAcademic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK, AZURE InvestigatorsAGO Breast Cancer GroupAlbert Einstein College of Medicine, Bronx, New York, USA, PrE0102 TrialAllegheny General Hospital, Pittsburgh, USAArbeitsgemeinschaft Gynäkologische OnkologieBarts Cancer Institute, Queen Mary University of London, IMpassion130 TrialBaylor-Sammons Cancer Center, Dallas, and US Oncology, Houston, USABreast and Gynecologic Cancer Medicine Service, Sloan-Kettering Institute for Cancer Research, New York, USABreast Cancer International Research Group, BCIRG 001 StudieBreast Cancer International Research Group, BCIRG 006 StudieBreast Cancer Now Research Centre, The Institute of Cancer Research, London, the TNT trialBreast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College LondonBreast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia, ExteNETBreast Cancer Unit, Kyoto University Hospital, JapanBreast Center, University of Munich, GermanyBreast Center Kantonsspital St. Gallen, Schweiz, eLEcTRA trialBreast Oncology, Department of Medicine und Robert H. Lurie Comprehensive Cancer Center, Chicago, USACancer and Leukemia Group B, Intergroup Trial C9741Cancer Research UK, Imperial College London, Hammersmith Hospitals Trust, London, UKCardiology Unit, Milan, ItalyCenter for Oncology Research and Treatment, Dallas, Texas, USAChinese Academy of Medical Sciences, Peking Union Medical College, Beijing, ChinaCleopatra Study Group, CLEOPATRA StudieClinical Trial Centre, University of Sydney, AustraliaClinical Trial Service Unit, Oxford, UK Clinical Trials Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale–IRCCS, NapolDana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA, IMpassion031 TrialDana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA IMpassion031 TrialDana-Farber Cancer Institute, Boston, CALGB 40302Dana-Farber Cancer Institute, Boston, MA, USA, monarcHER trialDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, PERTAIN StudieDan L. Duncan Comprehensive Cancer Center, Baylor College ofMedicine, Houston, PERTAIN StudieDavid Geffen School of Medicine at the University of California, Los Angeles, NATALEE trialDepartment of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TexasDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanDepartment of Hematology and Medical Oncology, Deaconess Hospital, Oncological Center of Stuttgart, GermanyDepartment of Internal Medicine-Cardiology, Philipps University, Marburg, GermanyDepartment of Medical Oncology, Dana–Farber Cancer Institute, BostonDepartment of Medical Oncology, Toulouse, Frankreich. FNCLCC PACS 01 StudieDepartment of Medical Oncology, Touluse, Frankreich. FNCLCC PACS 01 StudieDepartment of Medicine,Memorial Sloan Kettering Cancer Center, New York, USADepartment of Neurology at The Feinberg School of Medicine at Northwestern University, USDepartment of Obstetrics and Gynecology, Sana Klinikum Offenbach, HannaHDepartment of Obstetrics and Gynecology, University of Heidelberg, HeidelbergDepartment of Oncology, Auckland Hospital, AucklandDepartment of Oncology, Copenagen, DänemarkDepartment of Oncology, Copenagen, Dänemark, HERNATA StudieDepartment of Oncology, Institut Curie-St Cloud, FranceDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Shanghai Medical College, Fudan University, ChinaDepartment of Solid Tumor Oncology, Taussig Cancer Center, Cleveland, USA SWOG S0221Dipartimento di Oncologia, Napoli, ItalienDivision of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, HoustonDivision of Cancer Medicine, University of Texas M.D. Anderson Cancer CenterDivision of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, USADivision of Medical Oncology, Instituto Europeo di Oncologia, Milan, ItalyDivision of Medical Senology, European Institute of Oncology, Milan, ItalyDuke Cancer Institute, Durham, USAEastern Cooperative Oncology Group, Philadelphia, USEMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigatorsEMILIA Study Group, EMILIA StudieFudan University Shanghai Cancer Center, Shanghai, People's Republic of China, CBCSG010 StudyFudan University Shanghai Cancer Center, Shanghai, People’s Republic of China, CBCSG010 StudyGBG Forschung, Neu-Isenburg, APHINITY Steering Committee and InvestigatorsGeparSixto StudieGerman Breast Group, Frankfurt, GermanyGerman Breast Group, GBG Forschungs, Martin-Behaim- Str. 12, Neu-Isenburg, KATHERINEGunma Prefectural Cancer Center, Takahayashinishi, Ota, Gunma, JapanHelios Klinikum Berlin-Buch, GermanyHelios Klinikum Berlin-Buch, Germany, GeparSeptoImperial Cancer Research Fund Clinical Oncology Unit, Churchill Hospital, Oxford, United KingdomInstitut Curie, Paris and Saint Cloud, France, EMERALD TrialInstitut Gustave Roussy, Villejuif, France, SOLAR-1 StudyInstitut Jules Bordet, Université Libre de Bruxelles, Belgien; BOLERO-2 StudieInternational Breast Cancer Center, Vall d'Hebron Institute of Oncology, Barcelona, Spain, KEYNOTE-355Jewish General Hospital, McGill University, Montreal, Quebec, CanadaKEYNOTE-522 InvestigatorsKlinik für Internistische Onkologie, Freiburg, DeutschlandKrankenhaus Nordwest und German Breast Group, FrankfurtLevine Cancer Institute, Atrium Health, Charlotte, NC, USA, FeDeriCa trialLoyola University Chicago Stritch School of Medicine, Maywood, USALudwig-Maximilians University of Munich, Campus Grosshadern, Munich, GermanyM.D. Anderson Cancer Center, Houston, USA, HER2CLIMB trialM.D. Anderson Cancer Center, University of Texas, Houston, EMBRACA StudieMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia, SAPPHIREMater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia, SAPPHIRE trialMayo Clinic, Rochester, MN, Monarch 3 trialMedical Oncology and Breast Unit, European Institute of Oncology (IRCCS), Milan,Italy, NorCap-CA223 TrialMedical University of Vienna, ABCSG-12 trialMemorial Sloan Kettering Cancer Center, New York, OlympiAD TrialMemorial Sloan Kettering Cancer Center, New York, USA, DESTINY-Breast01 trialMiriam Hospital and Alpert Medical School of Brown University, Providence, USA, CALGB 40603 (Alliance)National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, AustraliaNetherlands Cancer Institute, Amsterdam, Netherlands, TRAIN-2 trialNew York University Medical Center, New York, New York, USANorthwestern University, Breast Oncology, Division of Hematology/Oncology, Department of Medicine, Chicago, USAOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trialOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trial, sowie National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaOncologia Medica, San Raffaele Cancer Centre, Milan, Italy, NeoSphere trial sowie National Center for Tumor Diseases, University Hospital, Heidelberg, Germany, TryphaenaOnkologie Ravensburg, Elisabethenstraße 19, 88212, Ravensburg, Germany, VicTORia trialPeking University Cancer Hospital and Institute, Beijing, People's Republic of ChinaPerlmutter Cancer Center, New York University School of Medicine, KEYNOTE-086Primary breast cancer: ESMO Clinical Practice GuidelinesResearch Institute and Tennessee Oncology PLLC, Medical Oncology, Nashville, USA, tnAcity trialRoyal Marsden Hospital, London, United KingdomRoyal Marsden Hospital and Institute of Cancer Research, London, PALOMA-3Royal Marsden NHS Foundation Trust, London, United Kingdom, monarchE trialSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, KCSG-BR15-10Sandro Pitigliani Medical Oncology Unit, Hospital Prato, ItalienSarah Cannon Research Institute, Nashville, USASarah Connor Reearch Inst. Nashville TN USASint Augustinus-University of Antwerp, Antwerp, Belgium, JAVELIN studySOLTI Breast Cancer Cooperative Group, Barcelona, Spain, NALA TrialSouth West Wales Cancer Institute, University of Wales, Wales, UK, TEXAS StudieSpanish Breast Cancer Research Group, GEICAM trialSt. Bortolo Hospital, Vicenza, ItalyStanford University, School of Medicine, MONARCH 2TAnDEM studyTaxotere EXperience with Anthracyclines Study; TEXAS StudieTh3resa Studiengruppe, TH3RESA StudieThe AGO Breast and the German Breast Group GAIN-2 StudienprotokollThe Central European Cooperative Oncology Group, TURANDOT StudieThe Eastern Cooperative Oncology Group, Southwest Oncology Group, Cancer and Leukemia Group, Noth Central Cancer Treatment GroupThe German Breast Group, Arbeitsgemeinschaft Gynäkologische Onkologie Breast Group InvestigatorsThe Medical Research Council Clinical Trials UnitThe Myocet Study GroupThe National Adjuvant Breast and Bowel Project, Pittsburgh, USAThe Royal Marsden Hospital and Institute of Cancer Research, Surrey, United KingdomThe Royal Marsden NHS Foundation Trust, London, United Kingdom, ALTERNATIVE trialThe TAX 306 Study GroupTriple-B Study, The Netherlands Cancer Institute, ClinicalTrials.gov Identifier: NCT01898117U.S. Oncology, Inc, Houston, TXUCLA Medical Center, Santa Monica, CA, MONALEESA-3University of California Irvine Medical CenterUniversity of California Los Angeles, Los Angeles, CA, USA, PALOMA-1/TRIO-18University of California San Francisco Helen Diller Family Comprehensive Cancer Center, SOPHIA TrialUniversity of Kansas Medical Center, Westwood, KansasUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA, CALGB 49907 TrialUniversity of Texas M.D. Anderson Cancer Center, Houston, MONALEESA-7University of Texas M. D. Anderson Cancer Center, Houston, TXUS Oncology Research, Texas Oncology, Dallas, USAVall d’Hebron, University Hospital, Barcelona; Hospital Arnau de Vilanova, Lleida, SpainWest German Study Group, Moenchengladbach, Deutschland, WSG-ADAPT-TNWest German Study Group, Mönchengladbach, Germany, The Neoadjuvant WSG-TP-II Randomized Clinical TrialProtocols in Revision 251 protocols foundProtocols under revision.Abemaciclib 150 / Anastrozole 1, Breast Cancer (PID567)Abemaciclib 150 / Anastrozole 1, Breast Cancer, adjuvant (PID1785)Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1408)Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1409)Abemaciclib 150 / Letrozole 2.5, Breast Cancer (PID566)Abemaciclib 150 / Letrozole 2.5, Breast Cancer, Adjuvant (PID1786)Alpelisib 300 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1620)Alpelisib 300 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1621)Anastrozole 1 / Fulvestrant 500, Breast Cancer (PID1248)Anastrozole 1 / Breast Cancer (PID1233)Anastrozole 1, Breast Carcinoma, adjuvant (PID1581)Atezolizumab 1200, Breast Cancer, adjuvant (PID2425)Atezolizumab 840 / Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, cycle 4-5. (PID2424)Atezolizumab 840 / Nab-Paclitaxel 100, Breast Cancer (PID63)Atezolizumab 840 / Nab-Paclitaxel 125, Breast Cancer, neoadjuvant, cycle 1-3. (PID2423)Avelumab 800, Breast Cancer (PID66)Bevacizumab 15 / Paclitaxel 80 / Doxorubicin Liposomal 20 / Carboplatin 1.5, Breast Cancer, tripel-negative (PID754)Capecitabine 1000 / Bevacizumab 15, Breast Cancer (PID370)Capecitabine 1000 / Docetaxel 75, Breast Cancer, adjuvant, part A (PID1643)Capecitabine 1000 / Epirubicin 75 / Cyclophosphamide 500, Breast Cancer, adjuvant, part B (PID1644)Capecitabine 1000 / Margetuximab 15, Breast Cancer (PID1871)Capecitabine 1000 / Paclitaxel 175, Breast Cancer (PID380)Capecitabine 1000, Breast Carcinoma (PID2128)Capecitabine 1250 / Docetaxel 75, Breast Cancer (PID1685)Capecitabine 1250, Breast Cancer, adjuvant (PID1370)Carboplatin 150, Breast Cancer (PID2374)Carboplatin 5 / Cyclophosphamide 600, Breast Cancer (tripel-negative) (PID101)Carboplatin 6, Breast Cancer (PID1940)Cisplatin 30, Tumor, Various Organs (PID2371)Cisplatin 75 / Gemcitabine 1250, Breast Cancer (PID763)Clodronic Acid (1040/520), Breast Cancer, Adjuvant (PID944)CMF - Cyclophosphamide 100 / Methotrexate 40 / 5-fluorouracil 600, Breast Cancer (PID1153)CMF - Cyclophosphamide 100 / Methotrexate 40 / Fluorouracil 600, Breast Cancer, adjuvant (PID1540)CMF - Cyclophosphamide 600 / Methotrexate 40 / Fluorouracil 600, Breast Ca, adjuvant (PID100)Cyclophosphamide 50 / Methotrexate 2.5, Metastatic Breast Cancer (PID83)Cyclophosphamide 600 / Doxorubicin Liposomal 60, Breast Cancer (PID1686)Cyclophosphamide 600 / Doxorubicin Liposomal 75, Breast Cancer (PID386)Docetaxel 100, Breast Cancer (PID752)Docetaxel 35, Breast Cancer (PID753)Docetaxel 75 / Carboplatin 6 / Trastuzumab (4/2), Breast Cancer,adjuvant, cycle 1 (PID411)Docetaxel 75 / Carboplatin 6 / Trastuzumab 2, Breast Cancer, adjuvant, cycle 2+ (PID412)Docetaxel 75 / Carboplatin 6 / Trastuzumab 6, Breast Cancer, neoadjuvant, cycle 2+. (PID654)Docetaxel 75 / Carboplatin 6 / Trastuzumab 8, Breast Cancer, neoadjuvant, cycle 1. (PID655)Docetaxel 75 / Carboplatin 6, Breast Cancer (PID1664)Docetaxel 75 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID393)Docetaxel 75 / Gemcitabine 1000, Breast Cancer (PID372)Doxorubicin / Cyclophosphamide dose-dense x 4 followed by Paclitaxel 175 x 4, Breast Ca, adjuvant, Part B (PID403)Doxorubicin 20, Breast Carcinoma (PID2131)Doxorubicin 50 / Cyclophosphamide 500 / Docetaxel 75, Breast Cancer, Adjuvant (PID398)Doxorubicin 50 / Cyclophosphamide 500 / Docetaxel 75, Breast Cancer, neoadjuvant (PID593)Doxorubicin 50 / Docetaxel 75, Breast Cancer (PID378)Doxorubicin 60 / Cyclophosphamide 600 dose-dense x 4 followed by Paclitaxel 175 x 4, Breast Ca, adjuvant, Part A (PID402)Doxorubicin 60 / Cyclophosphamide 600 dose-dense x 4 followed by Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80 x 4, Breast Ca, adjuvant, Part B Cycle 1 (PID1753)Doxorubicin 60 / Cyclophosphamide 600 dose-dense x 4 followed by Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80 x 4, Breast Ca, adjuvant, Part B Cycle 2-4 (PID1754)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Docetaxel 100 x 4, Breast Ca, adjuvant, Part A (PID599)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Docetaxel 100 x 4, Breast Ca, adjuvant, Part B (PID395)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 175 x 4, Breast Ca, adjuvant, Part B (PID396)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 80 / Trastuzumab 2 x 12, Breast Ca, adjuvant, Part B Cycle 2+ (PID492)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 80 / Trastuzumab 4 x 12, Breast Ca, adjuvant, Part B Cycle 1 (PID491)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel 80 x 12, Breast Ca, adjuvant, Part B (PID397)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Paclitaxel, Breast Ca, adjuvant, Part A (PID394)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Pertuzumab 1200 / Trastuzumab 600 / Docetaxel 100 x 4, Breast Ca, adjuvant, Part B Cycle 1 (PID1751)Doxorubicin 60 / Cyclophosphamide 600 x 4 followed by Pertuzumab 600 / Trastuzumab 600 / Docetaxel 100 x 4, Breast Ca, adjuvant, Part B Cycle 2-4 (PID1752)Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer (PID381)Doxorubicin 60 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID478)Doxorubicin 60 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, Breast Cancer, adjuvant, Part A (PID1141)Doxorubicin 60 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, Breast Cancer, adjuvant, Part C (PID1143)Doxorubicin60 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, Breast Cancer, adjuvant, Part B (PID1142)Elacestrant 345, Breast Cancer (PID2515)Epirubicin 150 x 3 / Paclitaxel 225 x 3 / Cyclophosphamide 2500 x 3, dose-dense, Breast Cancer, adjuvant Part A (PID399)Epirubicin 150 x 3 / Paclitaxel 225 x 3 / Cyclophosphamide 2500 x 3, dose-dense, Breast Cancer, adjuvant Part B (PID400)Epirubicin 150 x 3 / Paclitaxel 225 x 3 / Cyclophosphamide 2500 x 3, dose-dense, Breast Cancer, adjuvant Part C (PID401)Epirubicin 75 / Cyclophosphamide 600, Breast Cancer (PID382)Epirubicin 75 / Docetaxel 75, Breast Cancer (PID379)Epirubicin 90 / Cyclophosphamide 600 x 4 followed by Docetaxel 100, Breast Ca, neoadjuvant, part A (PID404)Epirubicin 90 / Cyclophosphamide 600 x4 followed by Doce 100, Breast Ca, neoadjuvant, part B (PID405)Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID579)Epirubicin 90 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, dose-dense, Breast Cancer, adjuvant, Part A (PID86)Epirubicin 90 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, dose-dense, Breast Cancer, adjuvant, Part B (PID87)Epirubicin 90 x 4 / Paclitaxel 175 x 4 / Cyclophosphamide 600 x 4, dose-dense, Breast Cancer, adjuvant, Part C (PID88)Epirubicin 90, Breast Carcinoma (PID2130)Eribulin 1.23, Breast Cancer (PID387)Eribulin 1.4 / Margetuximab 15, Breast Cancer (PID1872)Everolimus 10 / Exemestane 25, Breast Cancer (PID371)Everolimus 10 / Fulvestrant 500, Breast Cancer, cycle 1 (PID1875)Everolimus 10 / Fulvestrant 500, Breast Cancer, cycle 2+ (PID1876)Exemestane 25, Breast Cancer, adjuvant (PID1582)Fluorouracil 500 / Epirubicin 100 / Cyclophosphamide 500 x 3 followed by Docetaxel 100 x 3, Breast Cancer, adjuvant, Part A (PID388)Fluorouracil 500 / Epirubicin 100 / Cyclophosphamide 500 x 3 followed by Docetaxel 100 x 3, Breast Cancer, adjuvant, Part B (PID389)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 6 / Pertuzumab 420, Breast Cancer, neoadjuvant, cycle 2-3 (PID1468)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 8 / Pertuzumab 840, Breast Cancer, neoadjuvant, cycle 1 (PID1467)Fluorouracil 500 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadjuvant, cycle 1-3 (PID1357)Fluorouracil 600 / Epirubicin 90 / Cyclophosphamide 600 / Trastuzumab 6, Breast Cancer, Adjuvant (PID759)Fulvestrant 500, Breast Cancer (PID552)Gemcitabine 1000 / Capecitabine 650, Breast Cancer (PID1684)Gemcitabine 1000 / Carboplatin 4 / Trastuzumab 6, Breast Cancer, Cycle 2+ (PID414)Gemcitabine 1000 / Carboplatin 4 / Trastuzumab 8, Breast Cancer, Cycle 1 (PID413)Gemcitabine 1000 / Carboplatin 4, Breast Cancer (PID383)Gemcitabine 1000 / Cisplatin 30, Breast Cancer (PID1683)Gemcitabine 1000 / Margetuximab 15, Breast Cancer (PID1873)Gemcitabine 1000 / Vinorelbine 25, Breast Cancer (PID1682)Gemcitabine 800, Breast Cancer (PID2133)Lapatinib 1250 / Capecitabine 1000, Breast Cancer (PID367)Lapatinib 1500 / Fulvestrant (500/250), Breast Cancer, Cycle 1 (PID1770)Lapatinib 1500 / Fulvestrant 250, Breast Cancer, Cycle 2+ (PID1771)Lapatinib 1500 / Letrozole 2.5, Breast Cancer (PID1772)Letrozole 2.5, Breast Cancer, adjuvant (PID1580)Mitoxantrone 12, Breast Cancer (PID1424)Nab-Paclitaxel 100 / Carboplatin 2 / Bevacizumab 10, Breast Ca (tripel-negative) (PID466)Nab-Paclitaxel 100 / Cyclophosphamide 600 / Trastuzumab 6, Breast Cancer, adjuvant Cycle 2+ (PID410)Nab-Paclitaxel 100 / Cyclophosphamide 600 / Trastuzumab 8, Breast Cancer, adjuvant, cycle 1 (PID409)Nab-Paclitaxel 100 / Cyclophosphamide 600, Breast Cancer, adjuvant (PID58)Nab-Paclitaxel 125 / Carboplatin 2, Breast Cancer (PID61)Nab-Paclitaxel 125 / Carboplatin 2, Breast Cancer, neoadjuvant (PID1371)Nab-Paclitaxel 125 / Trastuzumab (4/2), weekly, Breast Cancer Cycle 1 (PID427)Nab-Paclitaxel 125 / Trastuzumab 2, weekly, Breast Cancer Cycus 2+ (PID428)Nab-Paclitaxel 125 weekly, Breast Cancer (PID415)Nab-Paclitaxel 125, Breast Cancer, neoadj. (PID1354)Nab-Paclitaxel 125, Breast Cancer, Variant 1 (PID2512)Nab-Paclitaxel 150 weekly, Breast Cancer (PID114)Nab-Paclitaxel 260, Breast Cancer (PID98)Neratinib 240 / Capecitabine 750, Breast Cancer (PID1870)Neratinib 240, Breast Cancer (PID1415)Olaparib 300, Breast Cancer (PID1105)Olaparib 300, Breast Cancer, adjuvant (PID2134)Paclitaxel 100 / Carboplatin 2, Breast Cancer (PID1961)Paclitaxel 175 / Gemcitabine 1250, Breast Cancer (PID377)Paclitaxel 175, Breast Carcinoma (PID2132)Paclitaxel 175, Breast Cancer (tripel-negative) adjuvant (PID479)Paclitaxel 80 / Carboplatin 6, Breast Cancer (PID1552)Paclitaxel 80 / Trastuzumab 2, Breast Cancer, adjuvant, cycle 2-12 (PID933)Paclitaxel 80 / Trastuzumab 4, Breast Cancer adjuvant, Cycle 1 (PID932)Paclitaxel 80, Breast Carcinoma (PID2127)Paclitaxel 80, Breast Cancer, adjuvant (PID581)Paclitaxel 90 / Bevacizumab 10, Breast Cancer (PID120)Palbociclib 125 / Exemestane 25 / Leuprorelin 3.75, Breast Cancer (PID1532)Palbociclib 125 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID607)Palbociclib 125 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID822)Palbociclib 125 / Letrozole 2.5, Breast Cancer (PID823)Pegylated Liposomal Doxorubicin 40, Breast Cancer (PID914)Pembrolizumab 200 / Doxorubicin 60 / Cyclophosphamide 600, Breast Ca, neoadjuvant, cycle 5-8 (PID1466)Pembrolizumab 200 / Epirubicin 90 / Cyclophosphamide 600, Breast Ca, neoadjuvant, cycle 5-8 (PID1465)Pembrolizumab 200 / Nab-Paclitaxel 100, Breast Cancer (PID1930)Pembrolizumab 200 / Paclitaxel 80 / Carboplatin 5, Breast Cancer, neoadjuvant, cycle 1-4 (PID1464)Pembrolizumab 200 / Paclitaxel 90, Breast Cancer (PID1932)Pembrolizumab 200, Breast Ca, adjuvant, cycle 9-17 (PID1868)Pembrolizumab 200, Breast Cancer, Maintenance (PID1931)Pembrolizumab 200, Breast Cancer, First-Line (PID1324)Pembrolizumab 200, Breast Cancer, Second Line (PID1329)Pertuzumab 1200 / Trastuzumab 600 / Nab-Paclitaxel 125, Breast Cancer, Cycle 1 (PID1756)Pertuzumab 1200 / Trastuzumab 600 / Paclitaxel 80, Breast Cancer, Cycle 1 (PID1758)Pertuzumab 420 / Trastuzumab 6 / Anastrozole 1, Breast Cancer, Cycle 2+ (PID1500)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75 / Carboplatin 6, Breast Cancer, neoadjuvant, cycle 2-6 (PID1470)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, adjuvant, cycle 2-4 (PID1166)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, neoadjuvant, cycle 2-4, 4-6, or 5-6 (PID750)Pertuzumab 420 / Trastuzumab 6 / Docetaxel 75, Breast Cancer, Cycle 2+ (PID364)Pertuzumab 420 / Trastuzumab 6 / Epirubicin 90 / Cyclophosphamide 600, Breast Cancer, neoadj, cycle 2-5 (PID1410)Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, adjuvant, Cycle 2-9 (PID2442)Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Neoadjuvant, Cycle 2-4 (PID2434)Pertuzumab 420 / Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Cycle 2+ (PID1497)Pertuzumab 420 / Trastuzumab 6 / Nab-Paclitaxel 125, Breast Cancer, neoadj. cycle 2-4 (PID1356)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80 / Carboplatin 6, Breast Carcinoma, neoadjuvant, cycle 2-9 (PID2122)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Breast Cancer, adj. cycle 2-4 (PID1168)Pertuzumab 420 / Trastuzumab 6 / Paclitaxel 80, Breast Cancer, neoadjuvant, cycle 2-4 (PID2432)Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Breast Cancer, adjuvant, cycle 2-9 (PID2443)Pertuzumab 420 / Trastuzumab 6 / Tamoxifen 20, Breast Cancer, Neoadjuvant, Cycle 2-4 (PID2441)Pertuzumab 420 / Trastuzumab 6, Breast Cancer, adjuvant (PID1350)Pertuzumab 420 / Trastuzumab 6, Breast Cancer, Adjuvant, Cycle 5-18 (PID680)Pertuzumab 600 / Trastuzumab 600 / Nab-Paclitaxel 125, Breast Cancer, Cycle 2+ (PID1757)Pertuzumab 600 / Trastuzumab 600 / Paclitaxel 80, Breast Cancer, Cycle 2+ (PID1759)Pertuzumab 600 / Trastuzumab 600, Breast Ca, adjuvant, 5-18 (PID1755)Pertuzumab 600 / Trastuzumab 600, Breast Cancer (PID1760)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, Cycle 1 (PID361)Pertuzumab 840 / Trastuzumab 8 / Anastrozole 1, Breast Cancer, Cycle 1 (PID1498)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75 / Carboplatin 6, Breast Cancer, neoadjuvant, cycle 1 (PID1469)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, adjuvant, cycle 1 (PID1165)Pertuzumab 840 / Trastuzumab 8 / Docetaxel 75, Breast Cancer, neoadjuvant, cycle 1 or cycle 4 (PID589)Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Adjuvant, Cycle 1 (PID2451)Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Neoadjuvant, Cycle 1 (PID2433)Pertuzumab 840 / Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Cycle 1 (PID1496)Pertuzumab 840 / Trastuzumab 8 / Nab-Paclitaxel 125, Breast Cancer, neoadj. cycle 1 (PID1355)Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Breast Cancer, adj. cycle 1 (PID1167)Pertuzumab 840 / Trastuzumab 8 / Paclitaxel 80, Breast Cancer, neoadjuvant, cycle 1 (PID2431)Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Breast Cancer, adjuvant, cycle 1 (PID2450)Pertuzumab 840 / Trastuzumab 8 / Tamoxifen 20, Breast Cancer, neoadjuvant, cycle 1 (PID2440)Pertuzumab 840/ Trastuzumab 8/ Paclitaxel 80/ Carboplatin 6, Breast Carcinoma, neoadjuvant, cycle 1 (PID2121)Ribociclib 400 / Anastrozole 1 / Goserelin 3,6, Breast Cancer, adjuvant (PID2585)Ribociclib 400 / Letrozole 2.5 / Goserelin 3.6, Breast Cancer, adjuvant (PID2578)Ribociclib 600 / Fulvestrant 500, Breast Cancer (PID73)Ribociclib 600 / Letrozole 2.5 / Goserelin 3.6, Breast Cancer (PID1372)Ribociclib 600 / Letrozole 2.5, Breast Cancer (PID127)STUDY - GAIN 2 - dtEC-dtD, Epirubicin 38-120 / Cyclophosphamide 450-1200, Breast Cancer, Part A (PID558)STUDY - GAIN-2 - dtEC-dtD, Docetaxel (60-100), Breast Cancer, Part B (PID559)STUDY - GAIN-2 - EnPC, Cyclophosphamide 2000, Breast Cancer, Part C (PID557)STUDY - GAIN-2 - EnPC, Epirubicin 150, Breast Cancer, Part A (PID554)STUDY - GAIN-2 - EnPC, Nab-Paclitaxel 330, Breast Cancer, Part B (PID556)STUDY - GAIN-2 - Pertuzumab 420 / Trastuzumab 6, Breast Cancer, neoadjuvant, cycle 2-4 (PID768)STUDY - GAIN-2 - Pertuzumab 840 / Trastuzumab 8, Breast Cancer, neoadjuvant, cycle 1 (PID767)STUDY - GAIN-2 - Trastuzumab 6, Breast Cancer (PID786)STUDY - GAIN-2 - Trastuzumab 600, Breast Cancer (PID555)STUDY - GAIN-2 - Trastuzumab 8, Breast Cancer (PID785)Talazoparib 1, Breast Cancer (PID1420)Tamoxifen 20, Breast Cancer, adjuvant (PID1583)Thiotepa 15 / Hydrocortisone 30, Tumor, Various Organs (PID2372)Topotecan 0.4, Malignant Meningitis (PID2520)Trastuzumab (4/2) / Anastrozole 1, Breast Cancer, Cycle 1 (PID755)Trastuzumab 150, Malignant Meningitis (PID2523)Trastuzumab 2 / Anastrozole 1, Breast Cancer, Cycle 2+ (PID756)Trastuzumab 6 / Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 2+ (PID1602)Trastuzumab 6 / Docetaxel 100, Breast Cancer, Cycle 2+ (PID417)Trastuzumab 6 / Lapatinib 1000 / Letrozole 2.5, Breast Cancer, Cycle 2+ (PID1769)Trastuzumab 6 / Letrozole 2.5, Breast Cancer, Cycle 2+ (PID765)Trastuzumab 6 / Vinorelbine 30, Breast Cancer, Cycle 2+ (PID419)Trastuzumab 6, Breast Cancer, adjuvant, cycle 2+ (PID1688)Trastuzumab 6, Breast Cancer, adjuvant, cycle 2+ (PID1474)Trastuzumab 6, Breast Cancer, Cycle 2+ (PID385)Trastuzumab 6, Metastatic Breast Cancer, Cycle 2+ (PID760)Trastuzumab 600, Breast Cancer (PID1330)Trastuzumab 8 / Abemaciclib 150 / Fulvestrant 500, Breast Cancer, Cycle 1 (PID1601)Trastuzumab 8 / Docetaxel 100, Breast Cancer, Cycle 1 (PID416)Trastuzumab 8 / Lapatinib 1000 / Letrozole 2.5, Breast Cancer, Cycle 1 (PID1768)Trastuzumab 8 / Letrozole 2.5, Breast Cancer, Cycle 1 (PID764)Trastuzumab 8 / Vinorelbine 30, Breast Cancer, Cycle 1 (PID418)Trastuzumab 8, Breast Cancer, adjuvant, cycle 1 (PID1687)Trastuzumab 8, Breast Cancer, Cycle 1 (PID384)Trastuzumab 8, metastatic Breast Cancer, Cycle 1 (PID761)Trastuzumab 80, Malignant Meningitis, Cycle 1 (PID2526)Trastuzumab 80, Malignant Meningitis, Cycle 2 (PID2527)Trastuzumab 80, Malignant Meningitis, Cycle 3+ (PID2542)Trastuzumab Deruxtecan 5.4, Breast Cancer (PID1634)Trastuzumab Emtansine 3.6, Breast Cancer, adjuvant (PID1343)Trastuzumab Emtansine 3.6, Breast Cancer, Third Line (PID366)Trastuzumab Emtansine 3.6, Breast Cancer, Second Line (PID365)Trastuzumab Emtansine 3.6, Breast Cancer, Neoadjuvant (PID111)Trofosfamide 150, Breast Cancer (PID430)Trofosfamide 50, Breast Cancer (PID429)Tucatinib 300 / Capecitabine 1000 / Trastuzumab 6, Breast Cancer, Cycle 2+ (PID1762)Tucatinib 300 / Capecitabine 1000 / Trastuzumab 600, Breast Cancer (PID1763)Tucatinib 300 / Capecitabine 1000 / Trastuzumab 8, Breast Cancer, Cycle 1 (PID1761)Vinorelbine 25 / Capecitabine 1000 - Capecitabine 1000 Maintenance, Breast Cancer (PID1693)Vinorelbine 25 / Capecitabine 1000, Breast Cancer (PID1692)Vinorelbine 25, Breast Carcinoma (PID2129)Vinorelbine 30 / Fluorouracil 750, Breast Cancer (PID678)Vinorelbine 30 / Margetuximab 15, Breast Cancer (PID1874)Vinorelbine 30, Breast Cancer (PID739)Vinorelbine 40 / Cyclophosphamide 50 / Capecitabine 500, Breast Cancer (PID1377)Vinorelbine 60 / Capecitabine 1000, Breast Cancer, Cycle 1 (PID942)Vinorelbine 70, Breast Cancer (PID420)Vinorelbine 80 / Capecitabine 1000, Breast Cancer, Cycle 2+ (PID943)Zoledronic Acid 4, Breast Cancer, adjuvant (PID928)Zoledronic Acid 4, Breast Cancer, adjuvant (PID935)